Pacritinib is under clinical development by CTI BioPharma and currently in Phase I for Sezary Syndrome. According to GlobalData, Phase I drugs for Sezary Syndrome have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pacritinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pacritinib overview

PacritInib (Vonjo) is an anti neoplastic agent. it is formulated as capsules for oral route of administration, Vonjo indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50×109/L.

Pacritinib (BAX 2201, SB-1518, ONX-0803) is under development for the treatment of peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma/follicular helper T-cell (AITL/TFH) cutaneous T-cell lymphoma mycosis fungoides (MF) and Sezary syndrome (SS), myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis and graft versus host disease (GVHD). It is administered orally. It targets JAK2-selective kinase, FMS-like tyrosine kinase 3,colony stimulating factor 1 receptor (CSF1R) and interleukin-1 receptor-associated kinase 1 (IRAK1).

It was also under the development for the treatment of myelodysplastic syndrome, colorectal cancer, acute myelocytic leukemia (AML), chronic myelomonocytic leukemia (CMML), chronic lymphocytic leukemia (CLL) and lymphomas (mantle cell lymphoma, Hodgkin lymphoma, indolent lymphoma), coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

CTI BioPharma overview

CTI BioPharma is a biopharmaceutical company that acquires, develops, and commercializes novel therapies for a range of blood-related cancers. Its lead product, Pacritinib is intended for the treatment of patients with myeloproliferative diseases. Its product pipeline includes PACIFICA for the treatment of myelofibrosis patients with severe thrombocytopenia; PAC203 for the patients with ruxolitinib therapy failure; PRE-VENT for COVID-19; PERSIST 1 for all platelets count and PERSIST 2 for platelets counts less than thousand. Its commercialized product, Vonjo is targeted for the treatment of adult patients with myelofibrosis patients with severe thrombocytopenia. The company relies on third parties for manufacturing and marketing its products. CTI BioPharma is headquartered in Seattle, Washington, the US.

For a complete picture of Pacritinib’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.